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Infiltrating T-cell markers in cervical carcinogenesis: a
systematic review and meta-analysis
Tamara R. Litwin 1, Sarah R. Irvin1, Rebecca L. Chornock2, Vikrant V. Sahasrabuddhe3, Margaret Stanley4 and Nicolas Wentzensen1
BACKGROUND: The host adaptive immune response helps determine which cervical HPV infections persist and progress to
precancer and cancer, and systematic characterisation of T-cell infiltration would help inform key steps in cervical carcinogenesis.
METHODS: A systematic review and meta-analysis were conducted of infiltrating T-cells in normal cervix, low-grade lesions, high-
grade lesions, and invasive cancers including epithelial, stromal, and total tissue and the following markers: CD3, CD4, CD8, FoxP3,
CD25, and the CD4:CD8 ratio. An additional qualitative review summarised longitudinal data on associations between infiltrating T-
cells and cervical disease persistence, regression, progression, or prognosis.
RESULTS: There were fewer CD3+, CD4+, and CD8+ cells in cervical lesions and more cells in cancers compared to normal
epithelium. FoxP3 and CD25+ regulatory T-cell infiltration is high in persistent and precancerous lesions, and longitudinal data
show improved outcomes with lower regulatory T-cell levels.
CONCLUSIONS: Successful immune evasion may reduce T-cell infiltration in HPV infected and precancerous epithelium, while
invasive cancers are highly immunogenic, and regulatory T-cell infiltration increases with cervical disease progression.
Understanding these factors may have prognostic value and could aid in novel treatment development and clinical guidelines, but
published data are highly heterogeneous and leave important gaps to be filled by future studies.
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BACKGROUND
Cervical cancer is the most common gynaecologic cancer and has
very high burdens of incidence and mortality worldwide, with
over 569,000 cases and 311,000 deaths in 2018.1 While screening
has greatly reduced cervical cancer incidence in high income
settings and incidence will be further reduced by vaccination
programs, adolescent immunisation will not greatly impact cancer
incidence for the next several decades,2 and large disparities in
incidence are driven by disparities in vaccination and routine
screening.
Infection with one of a group of carcinogenic human
papillomaviruses (HPV) is the necessary cause of cervical cancer.3,4
Over 90 percent of genital HPV infections clear spontaneously
within two years,5 while those that persist may but do not always
progress to precancer.6 Even many high-grade lesions sponta-
neously regress or fail to progress, with evidence suggesting that
only 30 percent of cervical intraepithelial neoplasias grade 3 (CIN3)
progress to invasive cancer in 30 years after incomplete excision,
which may mimic natural history.7 While viral factors influence
which HPV infections persist and progress, it is hypothesised that
the host immune response plays a key role in determining
whether an HPV exposure results in infection, persistence,
progression, and ultimately carcinogenesis.8
Effector T-cells, or T lymphocytes, are a basic component of the
adaptive immune response to infectious agents such as viruses
that are characterised by expression of the cluster of differentia-
tion (CD) cell surface marker CD3. Major subsets of T-cells include
helper T-cells, which express CD4, and cytotoxic or killer T-cells,
which destroy infected cells and express CD8. Regulatory T-cells
suppress the immune response and commonly express FoxP3 and
CD25 in addition to CD4. The adaptive immune response is
characterised by complex interactions between these T-cell types
and many other components to clear infections without harming
uninfected host tissue.
The extent and composition of infiltrating immune cells in
cervical tissue affects the natural history of HPV infections because
the virus must evade both innate and adaptive immune responses
to establish a productive and persistent infection.9 HPV infections
remain localised in the epithelium and systemic immune response
is rare, so circulating inflammatory cells are not typically involved
in the immune response to genital HPV infection, and levels of
circulating immune markers in response to HPV infection are not
easily established.10–12 If the innate immune system is unable to
prevent an incipient infection, local T-cell responses are necessary
to clear the virus, including those mediated by lesion-infiltrating
cytotoxic and helper T-cells.9
Understanding the composition of T-cell infiltrates in the
progression of cervical disease would contribute to etiologic
understanding of cervical carcinogenesis as well as revealing
possibilities for the development of future clinical interventions.
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However, despite individual reports of specific markers in
population subsets, no collated reference values are available.
We, therefore, undertook a systematic review of immunohisto-
chemistry (IHC) and immunofluorescence (IF) literature on
infiltrating immune cell counts across cervical disease stages
including uninfected normal tissue, HPV infections or low-grade
lesions, high-grade lesions or precancers, and invasive cervical
squamous cell carcinoma.
METHODS
Population and measures of interest
The population of interest is women age 18 and above with
cervical tissue in one of the following cervical disease states:
normal tissue, HPV infected or low-grade lesions, high- grade
lesions or precancers, and invasive cervical cancer. The measures
of interest include quantified T cell marker prevalence (positive
cells per unit area) in epithelial, stromal, and total cervical tissue
for the following markers: CD3, CD4, CD8, CD4:CD8 ratio, FoxP3,
and CD25.
Study selection and inclusion criteria
The systematic review and meta-analysis were performed using
the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) structure for the conduct of systematic reviews
(Fig. 1). The search algorithm to identify peer-reviewed articles in
the PubMed database that quantified pre-specified immune cell
types was as follows:
“((cellular immune response) OR lymphocytes OR macrophages
OR APC OR (natural killer cells) OR monocytes OR (toll-like receptors)
OR t-cells OR CD11C OR CD33 OR CD23 OR CD37 OR CD53 OR
CD63 OR CD81 OR CD57 OR CD163 OR CD195 OR EMR1 OR IL-22 OR
CD25 OR CTLA4 OR GITR OR CD62L OR CCR7 OR CD44 OR CD127
OR STAT5 OR CCR4 OR APMs OR CD7 OR CD3 OR CD4 OR CD8
OR cytokines OR CD68 OR CD56 OR FOXP3 OR CD14 OR CD16 OR
CXCR3 OR TLR OR IL-6 or S100) AND ((cervix) OR (cervical cancer) OR
(CIN) OR (cervical intraepithelial neoplasia) OR (cervical precancer)
OR (cervical precancerous lesions) OR (human papillomavirus) OR
(HPV)) AND (IHC OR immunohistochemistry OR immunohistochem-
ical OR histology OR histologic OR FFPE OR (formalin-fixed paraffin
embedded) OR (formalin-fixed paraffin embedded) OR (formalin-
fixed paraffin-embedded) OR (formalin-fixed paraffin-embedded)
OR infiltrate OR infiltrating OR infiltration).”
The search was conducted through September 5th, 2019.
Eligible studies included original cross-sectional, cohort, and case-
control studies that used IHC or IF methods to identify T-cell
populations in cervical tissues, including biopsies, hysterectomy
specimens, or tissue microarray samples. Exclusion criteria
included studies of non-human animals, studies conducted
in vitro, studies not examining outcomes of interest (cervical
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Fig. 1 PRISMA diagram. The initial and updated PubMed searches plus two additional records identified during the full-text review resulted
in total of 4741 records reviewed. After title and abstract review, 3789 records were excluded leaving 952 for full-text review. The full-text
review excluded an additional 716 records, leaving 236 records for potential abstraction. Of these, 72 were not abstracted for the reasons
indicated and 164 were abstracted. After limiting to the T-cell markers of interest, 73 records remained for inclusion in the quantitative meta-
analysis, longitudinal analysis, or qualitative summary of infiltrating T-cells in cervical tissue.
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cancer, pre-cancer or histologic changes of the cervix), other
methods (studies conducted with blood, serum or mucosa
samples, via flow cytometry, or fine needle aspiration), case
studies, studies lacking quantified immune markers of interest,
treatment or prevention studies without baseline data, studies
among pregnant women, and records that were not original
research articles. Where multiple studies published duplicative or
incremental results, including data from the same women, only
one was used. In order to focus on the adaptive T-cell immune
response, the marker set of interest was limited to CD3, CD4, CD8,
the CD4:CD8 ratio, FoxP3, and CD25. A search of the EMBASE
database was conducted using the same search terms and yielded
no additional papers eligible for inclusion.
An initial set of 150 titles and abstracts were reviewed
separately by three reviewers (SI, TL, and NW) to reach consensus
about inclusion standards. The remaining records underwent a
title review by SI or TL for potential inclusion, and reviewers
switched manuscript sets to complete abstract reviews. Full-texts
were evaluated by both investigators separately, and reference
lists of full-text papers were checked for additional relevant
references. Discrepancies between the reviewers for individual
studies were resolved by consensus.
Data abstraction and outcome characterisation
The primary outcome was mean positively stained cells per unit area
of sections of uterine cervical tissue. Where means were not
available, medians with interquartile ranges (IQR) or minimum and
maximum counts were abstracted. Data from figures not numeri-
cally reported in text were abstracted by estimating counts from
data points and error bars or box plot bounds. Conditional cell
counts were not abstracted except for the ratio of interest CD4:CD8
and the ratios CD25:CD4 and FoxP3:CD4 under the assumption that
CD25- and FoxP3-expressing regulatory T-cells are subsets of CD4-
expressing T-cells.13 We also conducted a quality review evaluating
the likelihood of confounding, selection bias, and information bias
with the signalling questions suggested for systematic reviews of
observational studies of epidemiology (COSMOS-E) placed in the
framework of quality assessment tool for diagnostic accuracy
studies-2 (QUADAS-2).14,15 Due to the descriptive nature of the
reports, the risk of reporting bias was considered low both within
and between studies and was not used for data synthesis.
Outcome standardisation
Outcome measures were standardised to mean and SD in cells/mm2
in preparation for meta-analysis. Measures reported in units of high
power fields (HPF) with 400x magnification were converted to cells/
mm2 by multiplying by a factor of 5.10 assuming an ocular field
number of 20 and the equivalent area of 1 HPF of 0.196mm2.16,17 If
the magnification was not specified, studies were excluded. Median
and IQR were converted to mean and SD according to the method
of Wan et al.18 Studies reporting results in units of cells per unit area
other than square millimetres were multiplied by the appropriate
conversion factor. If SD was not reported but a hypothesis test was
performed with a test statistic or p-value reported, SD was derived
from the appropriate test statistic formula to obtain study-specific
estimates. In studies reporting a mean and range, SD was computed
as described in Wan et al.18 Finally, simple imputation procedures
were used to obtain remaining missing SD values using gamma
distribution models within strata of marker, disease classification and
tissue type with at least two independent studies with SD values
reported.
In addition to the primary outcome, we abstracted the following
variables stratified by disease classification and immune marker
where available: age, HIV status, HPV status, tissue site (transfor-
mation zone, ectocervix, or endocervix), tissue type (epithelial,
stromal or total), country where the study was conducted, and
cancer stage and type (squamous or adenocarcinoma). Country of
origin, HPV status, and age were not considered in the final
analyses. Papers that did not designate epithelial or stromal tissue
were assumed to report values from entire slides or cores
consisting of both tissue types (total), and meta-analyses were
conducted separately for each of the three type designations. The
local immune environment and risk of cervical disease are greatly
altered in immunocompromised individuals, so studies of HIV
positive women were excluded from the present analysis.
Meta-analysis
Random-effects meta-analyses produced pooled estimates of
mean cells/mm2 and 95% confidence intervals for each marker
by tissue type within each disease level classification. Prioritisation
was in the following sequential order for samples taken from
multiple cervical locations in the same women: (1) transformation
zone (2) ectocervix (3) endocervix. ANOVA and Kruskal–Wallis tests
were used to evaluate differences across disease level means.
Analyses for CD3+, CD8+, CD4+ and the CD4:CD8 ratio
incorporated both explicitly reported and calculated values. Under
the assumption that CD3 positive T-cells are also positive for either
CD4 or CD8,19 means and SDs for any of these markers can be
derived from the values of the other two markers. A reported
value for the CD4:CD8 ratio is also informative under this
assumption if the absolute mean for at least one of CD3, CD4,
or CD8 is also reported, so means and SDs for the remaining
markers were calculated within populations that reported at least
two of the following: CD3, CD4, CD8, and the CD4:CD8 ratio.
Definitions and classifications of cervical disease
Cervical disease classification terminology and diagnoses are
complex and have evolved throughout the published literature.20
All historical and modern cervical disease classification were
included in the systematic review criteria, including normal/non-
dysplastic, cervical intra-epithelial neoplasia (CIN) grades 1-3, low-
grade CIN (lgCIN), high-grade CIN (hgCIN), low-grade and high-
grade squamous intraepithelial lesion (LSIL and HSIL), and
microinvasive or invasive squamous cell carcinoma or adenocarci-
noma with or without lymph node involvement. Carcinomas
in situ and neuroendocrine or other rare tumours were excluded,
as were genital warts (condylomas) and cervicitis.
Four disease classifications were evaluated in the primary
analysis: normal, low-grade neoplasia, high-grade neoplasia, and
cancer. Normal samples had no evidence of neoplasia and were
taken from healthy controls, hysterectomies for benign uterine
diseases, or screening populations. Samples reported as CIN1,
LSIL, and lgCIN were grouped as low-grade cervical neoplasia for
analysis, and CIN2, CIN3, HSIL and hgCIN were grouped as high-
grade cervical neoplasia. Because in general 90 percent of
invasive cervical cancers are squamous cell carcinomas (SCC)
and the immune infiltrates within the tissues of origin
(ectocervix or transformation zone for adenocarcinomas, endo-
cervix for squamous cancers) differ, we limited the quantitative
meta-analysis to studies reporting only SCC or unspecified
invasive cervical carcinomas.21 Studies of only adenocarcinomas
were excluded.
Sensitivity analyses
Sensitivity analyses were performed to confirm that the data
abstraction and imputation processes did not substantially alter
the results. These included stratified analysis by study unit
designation (HPF versus cells per unit area), analysis of CD3,
CD4, CD8 and CD4:CD8 with only explicitly reported (non-derived)
data, including only the subset of cancer observations explicitly
reported as squamous cancer and excluding cancers of unspeci-
fied subtype, incorporating all cancer observations including both
squamous and adenocarcinomas in the cancer disease classifica-
tion, and excluding reports of cancer- or lesion-adjacent normal
tissue out of concern that these samples may not represent a truly
normal immune microenvironment.
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Analyses were completed using SAS version 9.4 (SAS Institute,
Cary NC) and R version 3.6.1 run on R Studio version 1.1.22,23 Meta-
analyses were completed and forest plots were generated using
the “meta” package version 4.9-524 and GraphPad Prism 8.
RESULTS
Systematic review
The PubMed search identified 4739 records, and two additional
records were identified in references of other records (Fig. 1). Title,
abstract, and full-text review yielded 236 manuscripts for potential
abstraction. At the abstraction stage, additional exclusion criteria
included duplicate populations and inadequate descriptions of
methods and results for abstraction of quantified marker data,
resulting in 72 additional manuscripts excluded. A total of
73 studies reported results of interest, including 61 studies with
quantitative counts of T-cell markers reported in a manner
suitable for meta-analysis (Table S1),25–85 9 studies reporting
CD25 levels which were qualitatively summarised, and 20 studies
reporting longitudinal data (some studies were included in
multiple categories). A quality review of all studies included
in the manuscript revealed many studies with the uncertain
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Fig. 2 Forest plots of T-cell infiltrate quantitative meta-analyses. Forest plots of meta-analyses of infiltrating T-cell markers across cervical
disease stages in total tissue, epithelium and stroma expressed as mean cells/mm2 with 95% confidence intervals for the following markers:
a CD3, b CD8, c CD4, d CD4:CD8 ratio, e FoxP3. There were no stromal normal FoxP3 reports, so this category is absent. CIN cervical
intraepithelial neoplasia, LG low grade, HG high grade, MRAW raw (untransformed) mean, CI confidence interval.
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likelihood of bias or confounding due to insufficiently
detailed reporting of patient populations and methods (Table S2).
In line with COSMOS-E guidelines, no studies were excluded
due to results of the quality review.14 HPV status was not
reported in studies of normal tissues (women without active HPV
infections) and ubiquitous HPV positivity can be assumed for all
other disease levels, so this variable was not included in the meta-
analyses.
Results summary
A formal meta-analysis was conducted of CD3 (pan T-cell), CD8
(cytotoxic T-cell), and CD4 (helper T-cell) counts at each of four
disease levels (normal, lgCIN, hgCIN, and invasive cancer) in each
of three tissue sections (total, epithelium, and stroma) according
to how results from each study were reported in the manuscripts
(Figs. 2 and S1). ANOVA and Kruskal–Wallis tests showed
statistically significant differences between disease levels only
for CD8 total tissue (p-values 0.016 and 0.011, respectively,
Figure S2), with the group differences driven by significant
pairwise differences between cancer and each other disease stage
(p-values 0.008 vs hgCIN, 0.049 vs lgCIN, and 0.024 vs normal
tissues). Heterogeneity (I2) between studies was high for all
markers (Fig. 2).
Pan T-cells (CD3+)
The overall pattern of CD3+ cells was the same in all three tissue
sections, with the lowest numbers of T-cells present in lgCIN and
hgCIN, higher numbers in normal cells, and the highest numbers
in cancer (Figs. 2a and S1A). In total tissue, normal tissue had a
mean of 341 cells/mm2 (95% CI 81–601); lgCIN had 164 (29–298);
hgCIN had 214 (77–352); and cancer had 712 (447–977). In
epithelium, normal tissue had a mean of 146 cells/mm2 (104–187);
lgCIN had 65 (36–94); hgCIN had 137 (103–170); and cancer had
247 (178–317). Stromal tissue adjacent to normal epithelium had a
mean of 381 cells/mm2 (130–632); lgCIN was 303 (193–413); hgCIN
was 458 (358–557); and cancer was 838 (560–1117).
Killer T-cells (CD8+)
CD8+ cell patterns in epithelial and lesion-adjacent stromal tissue
were mostly similar to those for overall CD3+ T-cell count, with
higher infiltration in normal and tumour epithelial and adjacent
stromal tissue and lower infiltration in lgCIN and hgCIN (Figs. 2b
and S1B). In epithelium, normal tissue had a mean of 137 cells/
mm2 (95% CI 76–199); lgCIN had 37 (19–55); hgCIN had 46
(25–66); and cancer had 126 (97–155). In stroma, normal tissue
had a mean of 247 cells/mm2 (136–358); lgCIN had 157 (50–264);
hgCIN had 174 (108–240); and cancer had 395 (274–517).
Helper T-cells (CD4+)
The meta-analysis of CD4+ helper T-cells also revealed higher
infiltration in normal and cancer tissue and lower infiltration in
lgCIN and hgCIN tissue, most notably in hgCIN (Figs. 2c and S1C).
In total tissue, normal tissue had a mean of 209 cells/mm2 (95% CI
44–375); lgCIN had 139 (7–271); hgCIN had 143 (79–206); and
cancer had 287 (191–383). In epithelium, normal tissue had a
mean of 94 cells/mm2 (63–125); lgCIN had 19 (11–27); hgCIN had
16 (6–27) and cancer had 52 (38–67). In stroma, normal tissue had
a mean of 149 cells/mm2 (52–246); lgCIN had 142 (94–190); hgCIN
had 60 (27–92); and cancer had 185 (122–249).
CD4/CD8 ratio
CD4:CD8 ratios varied widely across cervical disease stages. A few
disease stage-tissue type combinations revealed higher CD8 than
CD4 levels (normal stroma, hgCIN total tissue, and cancerous
epithelium), but most confidence intervals included the null value
of one (Figs. 2D and S1D). There was no significant decrease in the
CD4:CD8 ratio in tumour tissue, although there is a suggestion of
such a decrease in epithelium (intratumoural tissue).
Regulatory T-cells (FoxP3+ and CD25+)
There was no clear pattern to the number of FoxP3+ regulatory
cells/mm2 at each disease level in epithelial tissue and high
heterogeneity in total tissue, while there was an increase across
lgCIN, hgCIN, and cancer in lesion-adjacent stromal tissue with no
studies reporting FoxP3 levels in normal stroma (Figs. 2E and S1E).
Some tissue type-disease level combinations had a single report,
which was reproduced in the figure without pooling for meta-
analysis. In total tissue, normal tissue had a mean of 107 cells/mm2
(95% CI -104–318); lgCIN had 4 (1–7); hgCIN had 52 (41–63); and
cancer had 391 (282–500). In epithelium, normal tissue had a
mean of 19 cells/mm2 (3–36); lgCIN had 0.4 (0.3–0.4); hgCIN had 7
(0–15); and cancer had 8 (6–10). In stroma, normal tissue had no
studies reporting, while lgCIN had a mean of 7 cells/mm2 (6–8);
hgCIN had 9 (3–15); and cancer had 56 (45–67). FoxP3
interpretation was limited by low numbers and low quality of
studies in many of the categories including lgCIN epithelium and
stroma in a single study each and no manuscripts reporting
normal stromal tissue. One manuscript which was not suitable for
meta-analysis reported a significant trend towards increasing
FoxP3 infiltration with increasing severity of cervical disease.86
CD25 data were not formally meta-analysed due to insufficient
study numbers (Table S3). However, several independent reports
suggested that CD25 positive cell levels and the proportion of
CD4+ or CD8+ cells which were also CD25+ increased with
increasing severity of cervical disease in both epithelial and lesion-
adjacent stromal tissue.26,87 Additionally, there were reports of
increasing FoxP3 as a proportion of CD4+ or CD8+ cells with
increased disease severity as well as confirmation that FoxP3 and
CD25 are generally co-expressed and may therefore be used
interchangeably as regulatory T cell indicators.26,62,88 Consistent
with the idea that an increased regulatory T-cell population is
associated with worse disease, there was also a report of greater
regulatory T-cell-associated cytokine profile in hgCIN compared to
lgCIN68 and a report of an association between lower CD25 levels
and lower CD25:CD4 and CD25:CD8 ratios and the regression of
hgCIN.67,89 Several studies suggested that the regulatory T-cell
(FoxP3+ and/or CD25+) presence was greater in stroma or
peritumoural tissue than in the epithelium or intratumoural tissue,
especially as carcinogenesis progressed.26,30,52,67,88,89 Finally, there
were also several reports that in hgCIN lesions, HPV16 infections
are associated with higher CD25+ infiltration levels than other
HPV types.67,87,89
Sensitivity analyses
Several sensitivity analyses were conducted to determine if results
were robust to various analytical decisions. These included
stratifying the meta-analysis into reports of cells/unit area and
reports of cells/HPF; restricting the analysis to explicitly measured
data for CD3, CD4, CD8, and the CD4:CD8 ratio rather than
including imputed values for these markers; excluding all not-
explicitly squamous cancers; including all cancers including
adenocarcinomas; and excluding reports included cancer- or
lesion-adjacent tissue from the normal tissue analysis. The
observed patterns of immune cells infiltration were generally
robust to sensitivity checks, though there were losses of clarity
and increases in confidence intervals as study numbers decreased
in many categories, sometimes to no studies or a single study,
making interpretation challenging (Table S4).
Longitudinal analysis of T-cell markers
In addition to overall quantification of T-cell markers, 20
references included relevant longitudinal or follow-up data on
the effect of infiltrating T-cell markers on regression, progression,
recurrence or patient survival (Table 1). Among studies that
followed women with CIN lesions for regression, persistence,
progression, or recurrence after treatment, several reported no
association between CD3 pan T-cell count and clinical course of
Infiltrating T-cell markers in cervical carcinogenesis: a systematic. . .
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CIN lesions, while one study associated high CD3 with lesion
recurrence after conisation.59,81,90,91 For CD8+ cells, five studies
reported no significant association with regression, progression,
persistence, or recurrence.59,66,81,90,91 Four studies reported an
association between high CD8 infiltration and CIN lesion regres-
sion: two used statistical tests to compare CD8+ quantities in
persistent infections to those that regressed,89,92 one modelled
the hazard of regression for those with high vs low CD8+
expression,67 and one reported a suggestive association between
highly active infiltrating CD8+ T-cells and lesion regression.85 For
CD4+ helper T-cells, one study reported that lower CD4 levels are
associated with recurrence, while five studies showed no
association.66,81,85,90,91 A reduced CD4:CD8 ratio was associated
with both increased CIN lesion regression and decreased
progression, although one study showed no association.81,90,91
For regulatory T-cells, two manuscripts analysing the same dataset
found lower CD25 and lower CD25:CD4 and CD25:CD8 ratios
associated with regression in hgCIN,67,89 while one study reported
no association between FoxP3 levels and lgCIN regression.85 In
sum, reports of infiltrating T-cells on CIN natural history are mixed
but generally suggest that greater numbers of (non-regulatory) T-
cells are observed with improved outcomes.
Among analyses of cancer relapse or survival, most studies
detected significant improvements in prognosis with increased
infiltrating T-cell populations. Intratumoural or peritumoural CD3+
cells were associated with increased overall survival and disease-
free survival, lower rates of relapse, earlier stage disease and
smaller tumour size at diagnosis, and reduced lymph node
spread.32,63,73,93,94 One study reported that higher CD3+ infiltra-
tion was associated with disease-free survival in adenocarcinoma
patients.73 The picture for CD8+ was more mixed, with one study
showing a significant association between increased CD8 and
lower overall survival, one showing association with decreased risk
of relapse, one study showing an association with improved
overall survival (for both intratumoural/epithelial and peritumoural
(lesion-adjacent)/stromal CD8) in early stage cancer only, and
other studies suggesting no association with overall or
progression-free survival.40,77,94–96 For CD4, two studies showed
an association between infiltrate density and reduced relapse or
increased survival, while one showed no association with overall
or progression-free survival and a fourth detected an association
only for late stage disease.77,94,95,97 For the CD4:CD8 ratio, there is
one report of an increased ratio associated with 5-year survival
and one of no association.77,94 For regulatory T-cells, two studies
reported that infiltrating FoxP3+ cells are associated with
decreased survival, one reported no association and one
adenocarcinoma study linked FoxP3 with improved survi-
val.51,73,77,98 Overall, the literature mostly reports that infiltrating
CD3 and CD4 T-cells have a positive effect on cervical cancer
prognosis, while regulatory T-cells may have a negative effect.99
DISCUSSION
A systematic review and meta-analysis were undertaken to
establish how infiltrating T-cell populations vary across cervical
disease stages. Studies of infiltrating CD3, CD4, CD8, FoxP3, or
CD25 positive cells and the CD4:CD8 ratio in the epithelium,
stroma, or total tissue of normal, lgCIN, hgCIN, or cancer were
abstracted for inclusion in the review. The results suggest a
pattern of higher T-cell infiltration in normal and especially in
cancerous cervical tissue and lower infiltration in low- and high-
grade CIN for CD3, CD4, and CD8 across tissue types, with a few
deviations (Fig. 3).
CD3 is a pan-T-cell marker, incorporating many subsets of
T-cells that express and release various receptors and cytokines.100
Infiltrating CD3 levels in cervical lesions and tumours may give an
indication of general immune activity as the cervical disease
progresses. The reduction in infiltrating T-cells in cervical lesions
relative to normal cervix supports that evasion of the adaptive
immune system by active and transformed HPV infections is
central to the development of cervical cancer. The absolute
numbers of infiltrating CD3+ cells reported were higher in stromal
than in epithelial tissue across disease stages, which suggests that
T cell responses may be more robust in or may originate in the
stromal tissue.101
Cells that express CD8 are commonly characterised as cytotoxic
or killer T-cells that destroy infected or damaged cells, although
the assumption that CD8+ cells signify active adaptive immunity
in cervical lesions remains unproven. Assuming CD8+ cells
function as an integral component of adaptive immunity, it is
expected that an increased presence of these cells would be
detected at the site of a tumour or active infection. However, as
for pan T-cells, the finding that cytotoxic T-cell counts are reduced
in CIN lesions fits with the overall picture of immune evasion as
characteristic of persistent HPV infections and cervical lesions. The
pattern for CD8 was not as consistent across tissue types as it was
for CD3 and was particularly difficult to interpret for total tissue
because of the wide confidence intervals for each disease level.
Helper T-cells activate cytotoxic T-cells and are characterised by
expression of CD4, although there are also subsets of CD4+ cells
with other functions such as regulatory T-cells. The pattern of







































Fig. 3 Conceptual model of infiltrating T-cells in cervical carcinogenesis. Normal cervical tissue is infiltrated by T-cells and T-cell subsets
that respond to infection as part of the adaptive immune response. When HPV infection becomes established and is not immunologically
cleared, it evades immune detection with reduced cytotoxic (CD8+) and helper (CD4+) T-cell infiltration in both the epithelium and adjacent
stromal tissue. It is unclear whether regulatory (CD25+, FoxP3+) T-cell infiltration is affected but some evidence suggests it begins to increase.
When HPV infections persist and progress to cervical precancer, pro-immune T-cell subsets continue to be suppressed and regulatory
(inhibitory T-cells) amplified. If the lesion progresses to invasive cancer, a highly immunogenic state is reached with high levels of pan,
cytotoxic, and helper T-cells in the surrounding stroma and to some extent in the tumour itself. Regulatory T-cells may be relatively high,
resulting in a worse prognosis, or low, resulting in a better prognosis.
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infiltrate in both low- and high-grade lesions relative to normal
tissue, and the greatest infiltration in cancer. It has been reported
that T-cell responses to HPV E2, a marker of productive infection,
are associated with regression, while T-cell responses to HPV E6, a
marker of transforming infection, are associated with persis-
tence.102 However, T-cell specificity cannot be detected using
conventional immunohistochemical techniques.
Regulatory T-cells inhibit the immune response and may
therefore promote carcinogenesis, in contrast to T-cells overall
which are associated with suppression of carcinogenesis. Indeed, a
previous analysis, albeit of only two studies, concluded that high
levels of FoxP3+ cells are associated with significantly reduced
overall survival in cervical cancer.103 Our findings in the FoxP3
meta-analysis and CD25 qualitative summary also suggest that an
increased presence of regulatory T-cells is associated with more
severe disease, that regulatory T-cell infiltration may inhibit the
immune response at all stages of cervical carcinogenesis, and that
this effect may be greater for HPV16, the most highly carcinogenic
HPV type. Further tissue analysis is required to confirm this
hypothesis.
The results were generally robust to sensitivity analyses, which
had small effects on absolute estimates overall. Stratifying by data
reporting method greatly reduced the number of studies in each
category, rendering the results uninterpretable. Restriction to
explicitly reported values for CD3, CD4, CD8, and the CD4:CD8
ratio likewise reduced the precision of the estimates, but the
overall patterns generally remained. Including only explicitly
squamous cancers and including all cancers including explicitly
adenocarcinomas had little effect because close to 90% of all
cervical cancers are squamous cell carcinomas, and possibly
because T-cell infiltrates increase in adenocarcinomas similarly to
the patterns in squamous cell carcinomas. Only two studies used
cancer-adjacent normal tissue, so removing them also had only
small effects on the estimates and no effect on the interpretation.
In addition to cross-sectional analyses, longitudinal data in both
CIN lesions and cancer suggest that increased overall and helper
T-cell subsets are associated with improved prognosis, a finding
that has also been observed in HPV positive vulvar squamous cell
carcinoma.104 Many studies showed no association, perhaps due
to lack of power, seven showed an association of greater numbers
of non-regulatory T cells or subsets with better outcomes, and just
one reported an association of greater T cells with worse
outcomes. As expected, the opposite is true of regulatory T cells,
with both studies that reported significant findings associating
lower levels of regulatory T cells with better outcomes. These
findings support models of HPV-associated carcinogenesis that
suggest immune evasion and suppression are critical to the
carcinogenesis process, but that once an invasive cancer is
established it is highly immunogenic. This is also consistent with
previous models of cellular immune response in cervical disease
progression.101,105
Limitations
The data on infiltrating immune cells in cervical tissue are highly
heterogeneous. Patient populations, laboratory techniques, environ-
mental exposures, and other factors may vary between studies, and
some studies report estimates from only the most highly infiltrated
parts of slides while others review randomly selected sections. Many
studies reported only semi-quantitative results, such as binary or
categorical classifications of immune infiltrates. While we were able
to include studies reporting cells/HPF that also reported the
microscope settings necessary to convert to an area-based
measurement, not all studies included such information, and in
some cases, it was necessary to impute or exclude study results. The
publication dates of abstracted manuscripts range from 1985 to
2018, and improvements in antibody quality and IHC technique over
this 30-year span may reduce the comparability of results over time.
In particular, the FoxP3 results must be qualified by the
understanding that there may not be good agreement between
different FoxP3 antibodies in the early literature, so absolute FoxP3
counts, in particular, may not be reliable.106 There is a clear need for
greater standardisation of reporting of tissue analysis results to
improve the ability to pool data across studies, as lack of
standardisation limited our ability to draw clear conclusions from
the data. Automated image analysis could also help improve
comparability between datasets. In addition, very few studies
reported HPV type, which affects HPV persistence and progression
to cervical precancer and cancer.107 The composition of lympho-
cytes has also been reported to vary by location within the cervix
(transformation zone, ectocervix, endocervix),108 but most studies
did not report this variable, so the current analysis does not take this
factor into account other than to include the transformation zone in
the analysis where multiple samples were taken from the same
woman because it is the most common site of squamous cancer
development. The present analysis also cannot address the reasons
for differential adaptive immune responses to HPV infection
between individuals, which likely include both environmental factors
such as coinfections with other sexually transmitted infections and
genetic factors such as HLA alleles.109
Studies of blood
Some previous studies have been undertaken in peripheral blood,
for instance it has been reported that CD25+ regulatory T-cell
levels, which can inhibit cytotoxic and helper T-cell responses, are
elevated in blood in patients with severe cervical lesions and
cancer.11,110 There is also evidence that the immune response is
deregulated during cervical carcinogenesis11,111,112 and that the
immunosuppressive environment generated by HPV is a critical
factor in disease progression.113 It has also been reported that
general immune response to challenges other than HPV itself may
be reduced in women with persistent HPV infections, with a
greater effect in older women, although the direction of any
causal relationship between suppressed immune function and
HPV persistence is unclear.114 However, in general, studies in
peripheral blood are not reflective of the local immune marker
population at the site of HPV infection,115 and it is important that
studies be conducted in tissue given the localised nature of the
immune response to HPV infection.
Future work
Further primary tissue analyses are clearly needed to clarify the
role of T-cell infiltrates in cervical disease. The current analysis
excluded immune infiltrates other than T-cells such as Langerhans
cell markers S100 and CD1a that also likely play a role in the
immune response to HPV infection and cervical carcinogenesis. In
addition, new technologies such as multiplex immunofluores-
cence and RNAscope could be applied to archival tissue to
characterise immune infiltrates and other features such as gene
expression in much greater detail.116 Studies of HIV positive
individuals were also excluded due to known differences in HPV-
associated carcinogenesis in immune-suppressed populations.
Future analyses of these additional markers and populations
may shed further light on the role of the adaptive immune system
in control of HPV infection. In addition to further etiologic
understanding of cervical carcinogenesis, improved knowledge of
patterns of T-cell infiltration across cervical carcinogenesis may
inform the development of therapeutic vaccines to induce lesion
regression by inducing a response to viral antigens E6 and E7,
both of which are markers of transforming HPV infection.117 It
could also provide insight into the use of immune checkpoint
inhibitors or other immunotherapies in cervical cancer patients.118
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